keyword
MENU ▼
Read by QxMD icon Read
search

Mantle cell lymphoma

keyword
https://www.readbyqxmd.com/read/28913874/an-algorithmic-approach-to-diagnose-haematolymphoid-neoplasms-in-effusion-by-combining-morphology-immunohistochemistry-and-molecular-cytogenetics
#1
L Chen, J S Zhang, D G Liu, D Cui, Z L Meng
OBJECTIVE: There are limited studies of cytology diagnosis of haematopoietic and lymphoid tumours in serosal effusion except for occasional case reports. We would like to demonstrate an algorithmic approach for accurate diagnosis, especially in patients without previous history. METHODS: We reviewed 36 cases of lymphoma diagnosed in serosal effusion following an algorithmic approach. Suspected tumour cells were classified into small, intermediate and large sizes and two characteristic forms of plasmacytoid and Reed Sternberg-like on smears (step 1), followed by utilising panels of immunohistochemical markers and Epstein-Barr encoding region in situ hybridisation on cell blocks (step 2)...
September 15, 2017: Cytopathology: Official Journal of the British Society for Clinical Cytology
https://www.readbyqxmd.com/read/28912297/cyclin-d1-negative-mantle-cell-lymphoma-with-aberrant-cd3-expression
#2
Anita Malek, Govind Bhagat
No abstract text is available yet for this article.
September 14, 2017: Blood
https://www.readbyqxmd.com/read/28911068/early-stage-mantle-cell-lymphoma-a-retrospective-analysis-from-the-international-lymphoma-radiation-oncology-group-ilrog
#3
B S Dabaja, A D Zelenetz, A K Ng, R W Tsang, S Qi, P K Allen, D Hodgson, U Ricardi, R T Hoppe, R Advani, P M Mauch, L S Constine, L Specht, Y Li, S A Terezakis, A Wirth, G Reinartz, H T Eich, B M P Aleman, P Barr, J Yahalom
Background: Mantle cell lymphoma (MCL) rarely presents as early-stage disease, but clinical observations suggest that patients who present with early-stage disease may have better outcomes than those with advanced-stage disease. Patients and methods: In this 13-institution study, we examined outcomes among 179 patients with early-stage (stage I or II) MCL in an attempt to identify prognostic factors that influence treatment selection and outcome. Variables examined included clinical characteristics, treatment modality, response to therapy, sites of failure, and survival...
September 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28910460/sudden-flank-pain-in-a-patient-receiving-ibrutinib-for-mantle-cell-lymphoma
#4
Yu Xi Terence Law, Lui Shiong Lee
No abstract text is available yet for this article.
September 14, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28905990/the-mtor-kinase-inhibitor-everolimus-synergistically-enhances-the-anti-tumor-effect-of-the-bruton-s-tyrosine-kinase-btk-inhibitor-pls-123-on-mantle-cell-lymphoma
#5
Jiao Li, Xiaogan Wang, Yan Xie, Zhitao Ying, Weiping Liu, Lingyan Ping, Chen Zhang, Zhengying Pan, Ning Ding, Yuqin Song, Jun Zhu
Mantle cell lymphoma (MCL) is an aggressive and incurable malignant disease. Despite of general chemotherapy, relapse and mortality are common, highlighting the need for the development of novel targeted drugs or combination of therapeutic regimens. Recently, several drugs that target the B-cell receptor (BCR) signaling pathway, especially the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib, have demonstrated notable therapeutic effects in relapsed/refractory patients, which indicate that pharmacological inhibition of BCR pathway holds promise in MCL treatment...
September 14, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/28901456/the-antitumor-effects-of-arsenic-trioxide-in-mantle-cell-lymphoma-via-targeting-wnt-%C3%AE-%C3%A2-catenin-pathway-and-dna-methyltransferase-1
#6
Xin-Yu Li, Ying Li, Lingyan Zhang, Xin Liu, Lili Feng, Xin Wang
Mantle cell lymphoma (MCL) is an aggressive non‑Hodgkin lymphoma (NHL) with poor prognosis. The rapid progression and frequently relapse make it urgent to identify therapeutic agents with potent antitumor effect. Increasing evidence indicated that dysregulation of Wnt/β‑catenin pathway and abnormal methylation appeared to promote tumorigenesis. Arsenic trioxide (As2O3, ATO) has been reported effective in many hematologic malignancies in recent studies, however, the mechanism and effects of ATO in MCL still need further research...
September 7, 2017: Oncology Reports
https://www.readbyqxmd.com/read/28899853/the-potential-for-chemotherapy-free-strategies-in-mantle-cell-lymphoma
#7
Peter Martin, Jia Ruan, John P Leonard
Mantle cell lymphoma (MCL) may be one of the few cancers where multiple chemotherapy and non-chemotherapy regimens are considered as standard. Despite the significant activity of chemotherapy in the first-line setting and beyond, its limitations are reflected in the relatively poor ultimate outcomes of patients with MCL treated in the real world. Highly proliferative MCL and those with TP53 mutations tend to respond poorly despite intensive cytotoxic therapies. Patients with co-morbidities and those that are geographically isolated may not have access to the regimens that may appear most promising in clinical trials...
September 12, 2017: Blood
https://www.readbyqxmd.com/read/28894694/evaluation-of-partial-breast-reirradiation-with-intraoperative-radiotherapy-after-prior-thoracic-radiation-a-single-institution-report-of-outcomes-and-toxicity
#8
Christine Chin, Priya Jadeja, Bret Taback, David P Horowitz, Sheldon M Feldman, Richard Ha, Eileen P Connolly
INTRODUCTION: Mastectomy is the current standard of care for ipsilateral breast tumor recurrences after prior whole breast irradiation (WBI). We report our single-institution experience with breast-conserving surgery (BCS) followed by intraoperative radiotherapy (IORT) as an alternative to salvage mastectomy for new or recurrent breast cancers that develop in the setting of prior thoracic radiation. METHODS: We performed an IRB-approved retrospective review of patients treated with breast IORT between September 2013 and November 2016...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28881919/newly-diagnosed-and-relapsed-mantle-cell-lymphoma-esmo-clinical-practice-guidelines-for-diagnosis-treatment-and-follow-up
#9
M Dreyling, E Campo, O Hermine, M Jerkeman, S Le Gouill, S Rule, O Shpilberg, J Walewski, M Ladetto
No abstract text is available yet for this article.
July 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28875507/the-etiology-of-b-cell-lymphoid-malignancies-with-a-focus-on-chronic-inflammation-and-infections
#10
Karin E Smedby, Maurilio Ponzoni
B-cell malignancies are a heterogeneous group of lymphoproliferative disorders with different molecular characteristics and clinical course. It is increasingly recognized that the group displays considerable heterogeneity also regarding etiologic factors. Here, we summarize the latest developments in the etiology of B-cell lymphoid malignancy subtypes focusing on immune perturbation. Severe immune suppression constitues a strong and well established risk factor for aggressive subtypes (e.g., diffuse large B-cell and Burkitt lymphoma), but appears unrelated to risk of common low-grade subtypes (e...
September 5, 2017: Journal of Internal Medicine
https://www.readbyqxmd.com/read/28873356/follicular-lymphoma-with-hyaline-vascular-castleman-like-features-analysis-of-6-cases-and-review-of-the-literature
#11
Sergio Pina-Oviedo, Roberto N Miranda, Pei Lin, John T Manning, L Jeffrey Medeiros
Follicular lymphoma (FL) with features reminiscent of hyaline-vascular Castleman disease (CD) is an unusual morphologic variant that may create diagnostic difficulties. To our knowledge, only 5 cases of this variant have been reported. We describe the clinicopathologic features of 6 cases including 2 men and 4 women with a median age of 63years (range, 41-77). Morphologically, all lymph node biopsy specimens showed at least a focal area of conventional FL; 4 cases showed neoplastic follicles with hyalinized blood vessels penetrating into germinal centers (lollipop-like lesions); 4 cases had interfollicular areas with increased vascular stroma, 2 cases showed small neoplastic follicles with prominent, onion skin-like mantle zones, and 1 case showed two or more germinal centers within follicles (twinning)...
September 2, 2017: Human Pathology
https://www.readbyqxmd.com/read/28860327/lacrimal-gland-and-extensive-subcutaneous-tissue-involvement-by-mantle-cell-lymphoma
#12
Iman Khodarahmi, Nasrin Ghesani
No abstract text is available yet for this article.
August 31, 2017: Blood
https://www.readbyqxmd.com/read/28858511/anchimerically-activated-protides-as-inhibitors-of-cap-dependent-translation-and-inducers-of-chemosensitization-in-mantle-cell-lymphoma
#13
Aniekan Okon, JingJing Han, Surendra Dawadi, Christos Demosthenous, Courtney C Aldrich, Mamta Gupta, Carston R Wagner
The cellular delivery of nucleotides through various pronucleotide strategies has expanded the utility of nucleosides as a therapeutic class. Although highly successful, the highly popular ProTide system relies on a four-step enzymatic and chemical process to liberate the corresponding monophosphate. To broaden the scope and reduce the number of steps required for monophosphate release, we have developed a strategy that depends on initial chemical activation by a sulfur atom of a methylthioalkyl protecting group, followed by enzymatic hydrolysis of the resulting phosphoramidate monoester...
September 20, 2017: Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/28858138/model-based-meta-analysis-of-progression-free-survival-in-non-hodgkin-lymphoma-patients
#14
REVIEW
Mengyao Li, Nimita Dave, Ahmed Hamed Salem, Kevin J Freise
BACKGROUND: Non-Hodgkin lymphoma (NHL) is a group of lymphoproliferative malignancies with varying treatment responses and progression-free survival (PFS) times. The objective of this study was to quantify the effect of treatment and patient-population characteristics on PFS in patients with NHL. METHODS: A database was developed from 513 NHL clinical trials reported from 1993 to 2015. Summary-level PFS was obtained from 112 of these trials, which included 155 cohorts and 11,824 patients...
September 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28857075/chimeric-antigen-receptor-t-cell-therapies-for-lymphoma
#15
REVIEW
Jennifer N Brudno, James N Kochenderfer
New therapies are needed for patients with Hodgkin or non-Hodgkin lymphomas that are resistant to standard therapies. Indeed, unresponsiveness to standard chemotherapy and relapse after autologous stem-cell transplantation are indicators of an especially poor prognosis. Chimeric antigen receptor (CAR) T cells are emerging as a novel treatment modality for these patients. Clinical trial data have demonstrated the potent activity of anti-CD19 CAR T cells against multiple subtypes of B-cell lymphoma, including diffuse large-B-cell lymphoma (DLBCL), follicular lymphoma, mantle-cell lymphoma, and marginal-zone lymphoma...
August 31, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28855351/non-hodgkin-and-hodgkin-lymphomas-select-for-overexpression-of-bclw
#16
Clare M Adams, Ramkrishna Mitra, Jerald Gong, Christine M Eischen
PURPOSE: B-cell lymphomas must acquire resistance to apoptosis during their development. We recently discovered BCLW, an anti-apoptotic BCL2 family member thought only to contribute to spermatogenesis, was overexpressed in diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma. To gain insight into the contribution of BCLW to B-cell lymphomas and its potential to confer resistance to BCL2 inhibitors, we investigated the expression of BCLW and the other anti-apoptotic BCL2 family members in six different B-cell lymphomas...
August 29, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28845330/mantle-cell-lymphoma-presenting-with-acute-bilateral-ophthalmoplegia
#17
Yaran Koban, Hatice Özlece, Orhan Ayar, Mustafa Koç, Hüseyin Çelik, Zeliha Yazar, Ayşe Burcu
A 72-year-old woman presented with acute onset of double vision, bilateral complete blepharoptosis, and nearly complete ophthalmoplegia. Orbital and brain magnetic resonance imaging were normal. Further investigation revealed bicytopenia with hepatosplenomegaly. Liver biopsy revealed mantle cell lymphoma. Cytology later showed the presence of mantle cells in cerebrospinal fluid analysis. Her ophthalmoplegia improved from her first cycle of systemic and intrathecal chemotherapy. To the best of our knowledge, this is the second case in the literature of mantle cell lymphoma with central nervous system involvement presenting with ophthalmoplegia...
August 2017: Turkish Journal of Ophthalmology
https://www.readbyqxmd.com/read/28842094/case-study-rare-case-of-mantle-cell-lymphoma-with-extranodal-involvement-in-the-foot
#18
Pauline Fu, Danielle Mercado, Vera Malezhik, Abul Ala Syed Rifat Mannan
Mantle cell lymphoma (MCL) is a rare type of non-Hodgkin lymphoma that commonly affects extranodal sites. The most commonly affected sites are the bone marrow, gastrointestinal tract, Waldeyer's ring, lung, and pleura. We report the case of an 80-year-old diabetic male, in MCL remission, who presented with a small dome-shaped nodule on his calf and an ipsilateral second digit non-healing ulceration after a traumatic fall. Despite surgical and conservative treatment, the wound worsened, resulting in histopathologic examination, which confirmed the presence of lymphocytes, indicating MCL relapse...
September 2017: Journal of Foot and Ankle Surgery: Official Publication of the American College of Foot and Ankle Surgeons
https://www.readbyqxmd.com/read/28838994/the-btk-inhibitor-cc-292-shows-activity-in-mantle-cell-lymphoma-and-synergizes-with-lenalidomide-and-nik-inhibitors-depending-on-the-nf-%C3%AE%C2%BAb-mutational-status
#19
Anna Vidal-Crespo, Vanina Rodriguez, Alba Matas-Céspedes, Eriong Lee, Alfredo Rivas-Delgado, Eva Giné, Alba Navarro, Sílvia Beà, Elías Campo, Armando López-Guillermo, Mónica López-Guerra, Gaël Roué, Dolors Colomer, Patricia Pérez-Galán
No abstract text is available yet for this article.
August 24, 2017: Haematologica
https://www.readbyqxmd.com/read/28832957/outcomes-in-370-patients-with-mantle-cell-lymphoma-treated-with-ibrutinib-a-pooled-analysis-from-three-open-label-studies
#20
Simon Rule, Martin Dreyling, Andre Goy, Georg Hess, Rebecca Auer, Brad Kahl, Nora Cavazos, Black Liu, Shiyi Yang, Fong Clow, Jenna D Goldberg, Darrin Beaupre, Jessica Vermeulen, Mark Wildgust, Michael Wang
Ibrutinib is highly active in treating mantle cell lymphoma (MCL), an aggressive B-cell lymphoma. We pooled data from three ibrutinib studies to explore the impact of baseline patient characteristics on treatment response. Patients with relapsed/refractory MCL (n = 370) treated with ibrutinib had an objective response rate (ORR) of 66% (20% complete response; 46% partial response); median duration of response (DOR), progression-free survival (PFS) and overall survival (OS) were 18·6, 12·8 and 25·0 months, respectively...
August 18, 2017: British Journal of Haematology
keyword
keyword
10129
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"